CNSystems Medizintechnik wins FDA clearance for CNAP Monitor 500

The CNAP Monitor 500 measures non-invasive and continuous blood pressure in real-time and can predict responsiveness to fluid administration. In the perioperative setting, detecting blood pressure drops and their cause in time is said to be crucial for peri- and postoperative outcome. However, until recently only invasive methods provided quality information to the clinician.

According to the company, CNAP provides reliable blood pressure monitoring comparable to invasive techniques and adds valuable information about fluid responsiveness of the patient non-invasively. This allows spreading the highest level of blood pressure monitoring to all perioperative settings where close blood pressure monitoring is indicated, but the risk and discomfort of invasive measurement is not justified.

CNAP is said to be the first continuous, non-invasive blood pressure management system ready for day-to-day clinical use. CNAP offers clinicians an easy-to-use and efficient way to measure the blood pressure and control the fluid state without discomfort to the patient, the company said.

Juergen Fortin, CEO of CNSystems, said: “CNAP is very well received amongst Europe’s anesthesiologists in only a short time and we are confident that the same will be true in the US where the perioperative market for continuous non-invasive blood pressure control is even more promising, with an estimated sales potential of approximately $190 million per annum.”